TrialFrontiers in immunology2021

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.

Hongyan Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.